Fundacio Ace Institut Catala De Neurociencies Aplicades

At Fundacio Ace Institut Catala De Neurociencies Aplicades in Barcelona, the Neurology program is centered on Alzheimer’s disease and related neurodegenerative disorders. The trials focus on understanding how to slow cognitive decline, reduce disease-related brain changes, and improve day-to-day function in people at different stages of illness.

• Studies in preclinical, early symptomatic, and mild to moderate Alzheimer’s disease
• Research on amyloid and tau as key targets in disease progression
• Evaluation of new therapies aimed at preserving cognition and function

This work includes efforts to test potential treatments, monitor safety and tolerability, and measure whether interventions can meaningfully delay worsening in memory and thinking skills.

The site also contributes to broader research in nervous system diseases, including conditions affecting the central nervous system and brain diseases more generally. These studies aim to improve diagnosis, track biological changes, and better understand how degenerative processes develop over time.

• Investigation of neurocognitive disorders and related decline
• Research into tauopathies and other neurodegenerative diseases
• Brain imaging and biomarker work to support earlier and more precise detection

By combining clinical assessment with biomarker and imaging-focused research, the Barcelona site helps advance tools that may improve how these disorders are identified and followed in routine care.

Alongside neurological research, the site has activity in psychiatry and psychology, especially where mental disorders overlap with Alzheimer’s disease and dementia. The goal is to better understand how cognitive symptoms affect overall mental functioning and quality of life.

• Studies involving mild cognitive impairment and early dementia
• Assessment of treatments intended to support cognition and everyday functioning
• Research that helps distinguish different patterns of neurocognitive impairment

These trials reflect a patient-centered approach, aiming not only to test new therapies but also to improve understanding of how Alzheimer’s disease affects behavior, thinking, and independence.